Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.
Lycia Therapeutics has raised $75.0M in total funding. The most recent round was Series D. The last funding was announced in June 2026.
Lycia Therapeutics's investors include Franklin Templeton, Eli Lilly, Janus Henderson Investors, Redmile Group, Balyasny Asset Management.
Lycia Therapeutics is headquartered in South San Francisco, United States.
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.
Lycia Therapeutics is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Lycia Therapeutics — Funding & Investors." VCBacked, June 25, 2026, https://www.vcbacked.co/company/lycia-therapeutics. Accessed July 30, 2026.
VCBacked. (2026). Lycia Therapeutics — Funding & Investors. Retrieved July 30, 2026, from https://www.vcbacked.co/company/lycia-therapeutics
{{cite web |title=Lycia Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/lycia-therapeutics |website=VCBacked |access-date=July 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated